PMID- 35311356
OWN - NLM
STAT- MEDLINE
DCOM- 20220412
LR  - 20231031
IS  - 1744-8042 (Electronic)
IS  - 1462-2416 (Linking)
VI  - 23
IP  - 6
DP  - 2022 Apr
TI  - KCNQ1 variant rs163184 is a potential biomarker of glycemic response to 
      exenatide.
PG  - 355-361
LID - 10.2217/pgs-2021-0154 [doi]
AB  - Aim: To examine the association between variant rs163184 in the type 2 diabetes 
      mellitus (T2DM) susceptibility gene KCNQ1 and exenatide glycemic response in the 
      Chinese population. Patients & methods: We included 100 T2DM patients from the 
      CONFIDENCE study and investigated the association between rs163184 and glycemic 
      response to exenatide, by using a multivariate linear model with adjustment for 
      baseline glucose status and other covariates. Results: The G allele of rs163184 
      was associated with a 0.34% (p = 0.016) lower glycosylated hemoglobin reduction 
      after 48 weeks of exenatide treatment. Similar significant associations were 
      observed when glycemic response to exenatide was evaluated with fasting blood 
      glucose or postprandial blood glucose reduction. Conclusion: We found that 
      rs163184 in the gene KCNQ1 was associated with reduced glycemic response to 
      exenatide in T2DM patients. The effect size observed in this study was large 
      enough to be considered clinically relevant in stratified medicine.
FAU - Geng, Zhaoxu
AU  - Geng Z
AUID- ORCID: 0000-0001-6714-8382
AD  - Institute of Biophysics, Chinese Academy of Sciences, Beijing, China.
AD  - College of Life Sciences, University of Chinese Academy of Sciences, Beijing, 
      China.
FAU - Li, Qian
AU  - Li Q
AD  - College of Life Sciences, University of Chinese Academy of Sciences, Beijing, 
      China.
FAU - Huang, Rong
AU  - Huang R
AD  - Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, 
      Shandong, China.
FAU - Wang, Jing
AU  - Wang J
AD  - College of Life Sciences, University of Chinese Academy of Sciences, Beijing, 
      China.
FAU - Weng, Jianping
AU  - Weng J
AD  - Department of Endocrinology, The First Affiliated Hospital of USTC, Division of 
      Life Sciences & Medicine, University of Science & Technology of China, Hefei, 
      Anhui, China.
FAU - Zhou, Kaixin
AU  - Zhou K
AD  - College of Life Sciences, University of Chinese Academy of Sciences, Beijing, 
      China.
FAU - Liang, Hua
AU  - Liang H
AD  - Department of Endocrinology & Metabolism, The Third Affiliated Hospital of 
      Sun Yat-sen University, Guangzhou, Guangdong, China.
FAU - Wang, You
AU  - Wang Y
AD  - Institute of Biophysics, Chinese Academy of Sciences, Beijing, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220321
PL  - England
TA  - Pharmacogenomics
JT  - Pharmacogenomics
JID - 100897350
RN  - 0 (Biomarkers)
RN  - 0 (Blood Glucose)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (KCNQ1 Potassium Channel)
RN  - 0 (KCNQ1 protein, human)
RN  - 9P1872D4OL (Exenatide)
SB  - IM
MH  - Biomarkers
MH  - Blood Glucose/genetics
MH  - *Diabetes Mellitus, Type 2/drug therapy/genetics
MH  - Exenatide/therapeutic use
MH  - Glycated Hemoglobin/analysis/genetics
MH  - Humans
MH  - Hypoglycemic Agents/therapeutic use
MH  - *KCNQ1 Potassium Channel/genetics
OTO - NOTNLM
OT  - KCNQ1
OT  - exenatide
OT  - glycemic response
OT  - rs163184
EDAT- 2022/03/22 06:00
MHDA- 2022/04/13 06:00
CRDT- 2022/03/21 12:14
PHST- 2022/03/22 06:00 [pubmed]
PHST- 2022/04/13 06:00 [medline]
PHST- 2022/03/21 12:14 [entrez]
AID - 10.2217/pgs-2021-0154 [doi]
PST - ppublish
SO  - Pharmacogenomics. 2022 Apr;23(6):355-361. doi: 10.2217/pgs-2021-0154. Epub 2022 
      Mar 21.